Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT(TM) for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Stock Information for Delcath Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Delcath Systems Inc.

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO(TM) in Liver-Dominant Metastatic Breast Cancer
Delcath Systems to Host First Quarter 2025 Earnings Call
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
Beta Bionics Announces Board Appointment of Gerard Michel
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.